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Background: Supervised consumption rooms or supervised injection facilities (SIFs) are venues that have
reduced the risk of needle sharing and deaths caused by drug overdose among people who inject drugs (PWID).
As a result of such a decline in the mortality rate, numerous studies have been able to illustrate its cost-effectiveness.
However, studies have neglected to examine the same phenomena for unsanctioned SIFs that are run by peer drug
users and provide assisted injections.
Methods: The current study will determine whether the former unsanctioned SIF, that provided assisted injection and
was operated by the grass root organization called Vancouver Area Network of Drug Users (VANDU), cost less than the
health care consequences of not having such a program in Vancouver, Canada. By analyzing data gathered in 2013,
this paper relies on two mathematical models to estimate the number of new HIV and HCV infections prevented by
the former unsanctioned facility in Vancouver’s Downtown Eastside.
Results: A conservative estimate indicates that the SIF location that provided assisted injections has a benefit-cost ratio of
33.1:1 due to its low operational cost. At the baseline sharing rate, the facility, on an average, reduced 81 HCV and 30 HIV
cases among PWID each year. Such reductions in blood borne infections among PWID resulted in annual savings worth
CAN$4.3 million dollars in health care expenditure. In addition to this, the current paper relies on a sensitivity analysis
based on different needle sharing rate scenarios.
Conclusions: The sensitivity analysis and the baseline rates indicate that funding SIF facilities operated by peer
drug users that facilitate assisted injection appear to be an efficient and effective use of financial resources in the
public health domain since they lead to a significant decline in the rate of mortality within a vulnerable
population.Background
The neighbourhood that consists of the ten blocks that
comprise the Downtown Eastside (DTES) of Vancouver
is the most impoverished urban area in Canada – one
that is marked with high rates of homelessness, drug
abuse, mental illness, and survival sex work [40, 67, 73, 78].
An estimated number of 5,000 people who inject drugs
(PWID) call this Vancouver neighbourhood their home
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license, and indicate if changes were made.population concentrated in this area has contributed to
the prevalence of human immunodeficiency virus (HIV)
and hepatitis C virus (HCV) to an extent that rivals its pres-
ence in developing countries during the late 1990s—with
cases of overdose similarly widespread [13, 40].
North America’s first and only government sanc-
tioned supervised injection facility (SIF), Insite, opened
in September 2003 to combat the growing public
health crisis facing the DTES [75, 77]. The public
health benefits of the facility in the DTES have been
well documented in over 60 peer reviewed studies.
However, the facility has been operating at full
capacity over the past decade and long line-upsistributed under the terms of the Creative Commons Attribution 4.0 International
y/4.0/), which permits unrestricted use, distribution, and reproduction in any
to the original author(s) and the source, provide a link to the Creative Commons
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especially during the welfare week, when people on
social assistance receive their government issued che-
ques ([65], p. 565).
There are now more than 92 SIFs operating across the
globe, and the potential of expanding Insite in the DTES
has been reviewed and endorsed in quite a few peer
reviewed studies [26, 48, 51, 65]. In addition to this, a
cost-benefit/cost-effectiveness study has suggested that
expanding the facility beyond its current location saves
tax payers’ money in terms of preventing new cases of
HIV in the DTES [4].
However, the Canadian conservative government’s ag-
gressive war on drugs, which has increased law enforce-
ment expenditure while simultaneously steering money
away from investment in harm reduction initiatives, has
raised questions regarding the efficiency of SIFs in the
media as well as in court [16, 25, 71, 72]. Furthermore, the
current Canadian conservative government is very un-
likely to approve new SIFs in Vancouver despite the
proven track record of such facilities across Europe and,
close to home, in Vancouver [22]. As numerous studies in
North America and Europe have highlighted, PWID are
not a homogenous group. Essentially, PWID have unique
needs that the current SIF operating in the DTES is not fit
to meet. Insite, North America’s only legally sanctioned
SIF, currently forbids sharing of drugs, assisted injection
and requires registration of clients [38]. Such noted re-
strictions, in addition to the high volume of usage by
PWID and lack of resources for people who smoke drugs
(e.g., crack and methamphetamine), discourage many drug
users to visit the small facility in the DTES.
Consequently, there is a pressing need for additional
SIFs that can accommodate various groups of PWID
in the DTES. In response to the general lack of pub-
lic health interventions, by the federal and provincial
government, for PWID in the DTES, a grass root
organization known as VANDU (Vancouver Area net-
work of drug users) was formed in the late 1990s
[27]. It composed of former and current drug users
[38]. VANDU, through activism and social justice ini-
tiatives, has been instrumental in changing the harm
reduction approach in the city of Vancouver [38].
Through their peer mobilization, and in an effort to
prevent the ongoing spread of HIV, HCV and overdose
in their community, VANDU opened an unsanctioned
SIF only a few blocks from Insite [51]. The small un-
sanctioned SIF, which had three tables and six chairs,
was operated by peers and was free to access. The facil-
ity could accommodate 6 potential PWID at the same
time. PWID that used the facility were provided with
free sterile drug use equipment (e.g., insulin syringes
with attached needles, bottles of sterile water for injec-
tion, latex condoms, alcohol swaps, disposal boxes andspoons), water, emergency care (in case of overdose),
and referral to addiction services by VANDU.
Moreover, the above mentioned unsanctioned SIF
allowed the peer drug users who operated the facility to
engage in assisted injection – something that is not
permitted under the mandates of Insite [51]. In effect,
it is estimated that 40 % of PWID require some sort of
assistance when injecting in the DTES [57]. This need
to rely on others to help with injection has placed many
users at increased risk of violence and drug related
harm [47, 51]. Furthermore, there are numerous studies
that indicate that drug users who require help injecting
drugs, when compared to those who self-inject, are at
greater risk of HIV and HCV infections as well as more
prone to indulge in the harmful practices of needle
sharing and drug overdose [35, 36, 43, 55, 57, 63, 76].
Assisted injection at VANDU’s former facility was
only permitted under auspices of strict harm reduction
practices that prohibited sharing of drugs and injection
paraphernalia [51]. Moreover, the peers that operated
the injection room were required to have CPR and
Naloxone training. Furthermore, the operators of the
injection room adopted certain precautionary mea-
sures: they were expected to “wear latex gloves, disin-
fect the injection site, and discard syringes in sharps
containers” after use ([51], p. 476). The unsanctioned
SIF, however, was forced to shut down in December
2013, when Vancouver Coastal Health threatened to
cut off all funding to VANDU’s operating budget of
CAN$200,000 [to convert the Canadian to American
dollar simply multiply by 0.81] unless the illegal facility
ceased to operate.
Two qualitative studies have demonstrated the effect-
iveness of the facilities in reducing risk factors for blood
borne infections “and other health risks, while allowing
people who require help injecting to escape drug scene
violence” ([51], p. 473; see also [52]). Numerous other
research has demonstrated the cost-effectiveness of
operating the only sanctioned SIF in North America
[3, 5, 10]. Furthermore, the operation and expansion of
potential sanctioned SIFs in numerous Canadian juris-
dictions, such as Montreal, Ottawa, Saskatoon, To-
ronto, and Victoria, has been found to be extremely
cost-effective [30–33]. However, the concept of an un-
sanctioned, peer-run SIF is controversial, particularly
because the potential cost-effectiveness impacts and
benefits of assisted injections are unknown.
Therefore, this study was conducted to examine the
effectiveness of an unsanctioned peer-run SIF, wherein
peers are known to be actively involved not only in run-
ning the facility, but also in overseeing assisted injec-
tion practices. The analysis used mathematical models
with conservative parameters to estimate the number of
HCV and HIV infections prevented as a result of an
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avoided were compared to the operational cost of the
unsanctioned facility, and then extended to consider




This study was approved by both the Simon Fraser
University Research Ethics Board and VANDU’s Execu-
tive Board. The data collected pertains to the number
of visits to the unsanctioned SIF, determined to be
8,886 per year, with an average of 657 per month. For
the current analysis, it was necessary to rely on a
model that could reflect the effects of providing clean
equipment and adopting safer injection behaviors in its
calculations. Drawing from the methodology of re-
search on the economic impact of a needle exchange
program in Edmonton, the current study uses a math-
ematical model to estimate the number of HCV and
HIV infections that could be prevented through the
establishment of an SIF [24]. The number of new HIV/
HCV infections avoided, (A), is calculated as follows:
New HIV=HCV infections Að Þ
¼ INsd 1− 1−qtð Þm½  ð1Þ
where (I) is the PWID population that is HIV or HCV
negative, (N) is the number of needles in circulation, (s)
is the rates of needle sharing, (d) is the percentage of
needles not cleaned before use, (q) is the HCV/HIV
prevalence in the PWID population, (t) is the probability
of HCV/HIV transmission when using an HIV/HCV in-
fected needle, and (m) is the number of sharing partners
when needles are shared.Table 1 Sources for variables used in mathematical modeling
Variable Value Source
Proportion of PWID HIV- (I) 77.46 % Petrar
Rate of Needle sharing (b) or (λ) 30 % Holtgr
Number of needles in circulation (N) 2000000 McCle
Percentage of needles not cleaned (d) 17.00 % Hope
Probability of HIV infections from a single injection
(t) or (α)
0.67 % Allard
Number of sharing partners (m) 1.38 Kozal e
Proportion of PWID HIV+ (q) 22.54 % Holtgr
Proportion PWID HCV- (I) 12.00 % Bayou
Proportion of PWID HCV+ (q) 88.00 % Bayou
Probability of HCV infection from single injection(t) 3 % Gore &
Proportion of HIV/HCV infected needles (β) 40.50 % Hope
Probability of needles cleaned (θ) 83 % IguchiThe model above has been adopted previously by six
costing studies [4, 28, 30–33]. To operationalize the
model, the data shown in Table 1 needs to be imputed
in excel programing and combined with the reduction in
the rate of needle sharing rates in order to calculate the
rate of blood borne infection reductions. The current
study also relies on a second model to calculate the
number of HIV infections avoided:
New HIV infection rate Að Þ ¼ 1−πð Þλ 1−θð Þβα ð2Þ
where (β) is the percentage of HIV infected needles, (π)
is the prevalence of HIV infections in the neighbor-
hood, (θ) is the probability that a borrowed syringe is
decontaminated, (α) is the probability of acquiring HIV
from a single injection with contaminated syringe and
(λ) is the rate of needle sharing. The second model was
used in the evaluation of New Haven needle depot by
Kaplan and O’Keefe [34], and subsequently used in
Pinkerton [60] Jozaghi et al. [31]) and Jozaghi et al.
[33]. The Kaplan model estimates the rate of infection.
Consequently, the rate of HIV infections was calculated
with and without the penitential SIF and then multi-
plied by the number of PWIDs to get the count of HIV
infections.
The ratio of cost-effectiveness was estimated by div-
iding the operational cost of the potential SIF by the
number of prevented blood borne infections such as
HCV or HIV. An estimation for cost–benefit ratio was
reached by dividing the cost savings, in terms of dis-
eases prevented, by the cost of the operations. Further-
more, according to Jozaghi et al. [31]), “marginal costs
and benefits are measurements for producing one more
unit. In contrast, the cumulative benefits and cost are
the running total of benefit and cost with eachet al. [58]); Tyndall et al. [69]
ave et al. [20]; Kerr et al. [37, 39]
an [50]; Buxton [8]
et al. [21]; Kaplan and O’Keefe [34]; Jacobs et al. [24]
[1]; Kaplan and O’Keefe [34]
t al. [41]; Jacobs et al. [24]
ave et al. [20]; Kerr et al. [37, 39]
mi & Zaric [5]
mi & Zaric [5]
Bird [15]
et al. [21]; Kaplan and O’Keefe [34])
& Bux [23]; Anderson et al. [2]; Kaplan and O’Keefe [34]); Jacobs et al. [24]
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proven to be a reliable way to control and account for
the number of uncertainties that may arise in mathem-
atical models. Similarly, this study relied on two sensi-
tivity analyses to control the number of assumptions
considered in this study. The first form of sensitivity
analysis was achieved by employing a secondary math-
ematical model to estimate the potential number of
HIV cases that have been prevented by establishing an
unsanctioned SIF in the DTES. Later, the rate of needle
sharing within the DTES was used to account for the
additional uncertainties presented in the model.
Assumptions
The cost-benefit and cost-effectiveness analysis of this
study relied on the number of HIV and HCV infections
prevented; nevertheless, there were a handful of param-
eters to be estimated, including the lifetime costs of
treating HIV and HCV infections, new HIV and HCV
cases prevented based on each additional facility, and
subsequently, the desirable number of facilities. For this
research, it was necessary to use a model that reflected
the effects of using clean injection equipment and safer
injecting behaviours in its calculations. Previous SIF
cost studies such as those conducted by Bayoumi and
Zaric [5], Pinkerton [60], Pinkerton [61], Andresen and
Boyd [3], Andresen and Jozaghi [4], Jozaghi and Jackson
[30], Jozaghi et al. [31]), Jozaghi et al. [32]) and Jozaghi
et al. [33] have concluded that SIFs are able to prevent
the risk of new HIV and HCV cases, since there will be
a certain number of known non-shared injections as
opposed to shared injections outside of the facility.
This study also chose to employ the behaviour change
incorporated, where it was assumed that those PWIDs
who attend a SIF are at 0.3 frequency to share needles
outside of an injection facility (Bravo et al. [7, 37, 39]).
The behavioural change is a phenomenon that has been
documented in the clientele of SIFs in Canada and
Europe, where such PWID are less likely to share their
needles once they leave the injection facility (Bravo et al.
[7, 37, 39]). This rate has been incorporated in Bayoumi
and Zaric [5], Bayoumi et al. [6], Andresen and Boyd [3],
Andresen and Jozaghi [4], Jozaghi [27, 28]), Jozaghi and
Jackson [30], Jozaghi et al. [31]), Jozaghi et al. [32]), and
Jozaghi et al. [33] because of the empirical evidence
shown in Kerr et al. [37, 39]) and Bravo et al. [7]. Ultim-
ately, similar to Bayoumi and Zaric [5], Bayoumi et al. [6],
Jozaghi [29], Jozaghi et al. [32]) and Jozaghi et al. [33],
this study considered 50 % of the reported effects of
a SIF on needle sharing. An odds ratio of 0.60 was
employed in the calculation to account for the lower
needle sharing rate for those PWID that visited the un-
sanctioned facility in the DTES so they could have ac-
cess to assisted injection.However, to stay on the conservative side, the odds
ratio was only employed twice: for the first and second
potential unsanctioned SIF where the facilities would be
able to accommodate 12 clients at the same time. The
behaviour change on the sharing variable indicates that
if a second unsanctioned SIF is established, further
behavioural changes may occur if and only if new PWID
become users of SIF [4]. If only current users of SIF use
the second SIF, simply performing more of their injec-
tions at SIF, no further behavioural changes can be
assumed. In other words, SIFs will only be attracting
returning clientele that will be visiting the SIF more fre-
quently because of availability of assisted injection in the
DTES [33].
Variables and parameters
Except for the rate of utilization at VANDU, the values
for both equations were drawn from Vancouver-specific
estimates, using scientific and medical literature where
city-specific estimates were not available. Fundamentally,
the cost-benefit/cost-effectiveness analysis of this study
relied on the behavioural change and the number of
HCV and HIV infections prevented. Also, the total num-
ber of injections in the DTES was calculated by multi-
plying the total population of PWID users and the
estimated number of injections per year (e.g., 5,000
PWID * 913 injections per year) [4, 20, 24, 44, 50].
The medical cost of new HIV infections
The success of ART (antiretroviral therapy) has not
been replicated amongst PWID due to the treatment’s
side-effects [17], as well as high rates of treatment
discontinuation among the marginalized population
[18, 59, 68, 75, 77]. For example, a study by Druyts
et al. [12] found a threefold risk of death among HIV-
infected individuals on ART in neighbourhoods with a
high concentration of PWID relative to those with a
high concentration of gay men, thereby leading to
poorer treatment uptake and adherence among PWID
[45]. However, it should be noted that recent research
by Meyer et al. [54] suggests that PWIDs are at a
significant risk in terms of being subject to health dis-
parities for treatment of HIV. This can be attributed
mainly due to denial of treatment by health care pro-
viders to ART and late start of treatment rather than
some of the noted issues related to discontinuation of
treatment and non-adherence. Nevertheless, the life-
time cost-savings from each averted case of HIV infec-
tion ranges from CAN$174,410 [14], to CAN$ 253,210
[9, 19, 62] and as high as CAN$289,970 with addition
of ART [70].
This study utilized the numerical figure of CAN
$210,555 – as reported in Pinkerton [60], Andresen and
Jozaghi [4], Jozaghi and Jackson [30], Jozaghi et al. [31]),
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analysis anticipated a lower cost of treatment for HIV
infections among PWID. This lower estimate was chosen
because PWID may experience certain self-imposed soci-
etal barriers, making them less likely to take full advantage
of public health care, especially the expensive ART pro-
gram [17, 54, 75, 77].
The medical cost of a new HCV infection
The cost of treating an HCV infection ranges from
CAN$30,000 [71, 72] to CAN$69,188 [49]. A lower
number of CAN$20,000 has also been suggested for
each completed patient course of treatment [42]. How-
ever, the value of CAN$35,143 reported in National
Centre in HIV Epidemiology and Clinical Research [56],
Jozaghi et al. [32], Jozaghi [27, 28], Jozaghi et al. [31],
and Jozaghi et al. [33] is the most appropriate for this
research, since the above mentioned studies considered
the costs for liver transplant cases, liver failure, and
hepatocellular carcinoma. Even so, it is essential to ac-
knowledge that the cost of treating an HCV infection is
changing rapidly as a direct consequence of the emer-
gence of more effective treatments that tend to be
shorter and significantly more expensive.
Cost of SIF
This analysis used the fixed operating cost of an exist-
ing SIF to estimate the total cost involved. The former
facility operated from Monday to Friday from 10-7 pm,
and from 4-7 pm on weekends. The staff of the former
unsanctioned SIF included volunteers that are pro-
vided with small stipends amounting collectively to
CAN$47,203 per year. When added to the total cost of
the rent and the injection equipment, estimated at
CAN$50,000, the total annual operating cost of the
facility becomes CAN$97,203.
Results
This research assessed whether VANDU’s unsanctioned
SIF has a net positive effect on the Canadian society,
and whether this initiative saves public health care funds
by averting new HIV and HCV infections. Therefore, the
expenses incurred for operating unsanctioned SIFs were
determined using two mathematical models. These pre-
dicted the number of new cases of HIV infections pre-
vented based on the sharing rate, which included the
impact of behavioural changes in injection activities
once outside of the unsanctioned SIF. For HCV infec-
tions, only the first mathematical model was used since
‘c’, the proportion of HCV infected needles in the second
mathematical model, remains unreported in any pub-
lished or unpublished research.
As shown in Table 1, numerous published peer-
reviewed studies were utilized to complete the analysis.As expected, according to the data in Tables 2 and 3,
increasing the scope of an unsanctioned SIF through site
expansion would decrease the overall rate of HIV infec-
tions. Based on Table 4, the second mathematical model
also predicts a range of 10-32 HIV infections, with mar-
ginal HIV cases ranging from 3-10.
Table 4, using the first and second mathematical
models, shows a substantial difference in the number of
new HIV infections prevented. The first model, based
on Tables 2 and 3, predicts 30-102 for HIV and 81-274
for HCV, with the marginal range being much smaller,
at 7-30 for HIV and 19-81 for HCV. According to
Andresen and Jozaghi [4], this disparity may be attrib-
uted to the first model that overestimated the cases of
HIV infection. However, both models predict that
VANDU’s unsanctioned SIF is cost-effective. For ex-
ample, according to Table 2, benefit-cost ratio for HIV
in the first model ranges from 31.6 to 64.9, and cost-
effectiveness for HIV ranges from $3,240 to $6,671.
The cumulative annual estimates of averted HCV cases
translates into a benefit-cost ratio ranging from 14.2 to
29.3, and cost-effectiveness value ranging from $1,200
to $2,483. In contrast, the marginal estimates of VAN-
DU’s unsanctioned SIF result in a much smaller return,
both in its benefit-cost and cost-effectiveness ratios.
For instance, the marginal benefit-cost ratio varies from
17.3 to 64.9 for HIV and 7.9 to 29.3 for HCV. The mar-
ginal cost-effectiveness value ranges from $3,240 to
$12,150 for HIV and from $1,200 to $4,418 for HCV.
Moreover, when the second mathematical model is
considered, as outlined in Table 4, averted cases of HIV
account for a substantial difference between the eco-
nomic evaluation of SIFs – especially in terms of the
cumulative versus the marginal estimates. For example,
according to data in Table 4, the cumulative annual esti-
mates of new HIV cases averted, based on the second
model, translate into a benefit-cost ratio ranging from
9.9 to 21.7, and cost-effectiveness value ranging from
$9,720 to $21,263. In contrast, the marginal estimates of
VANDU’s SIF expansion, based on the the second
model, result in a much smaller return, in both benefit-
cost and cost-effectiveness ratio. For instance, HIV’s
marginal benefit-cost ratio varies from 5.5 to 21.7 and
its marginal cost-effectiveness from $9,720 to $32,401.
The results from both mathematical models in this
paper demonstrate that VANDU’s unsanctioned SIF
establishment in the DTES saves taxpayers’ money.
Nevertheless, comparing the overall figures (such as cu-
mulative or marginal) seems to support the earlier
assumption that expanding unsanctioned SIFs through
unsanctioned practices such as assistance during injec-
tion will save money if it prevents even a modest
number of HIV and HCV infections per year. Finally, a
sensitivity analysis was conducted for the models
Table 2 The cumulative annual cost - effectiveness and cost – benefit of unsanctioned SIF in Vancouver using Jacobs et al.’s [24] model
Variables Annual cost of
operation














One SIF $97,203 25 % 30 81 $1,200 $3,240 29.3 64.9 94.3
(33 %, 16 %) (40, 20) (103, 59) ($944, $1,648) ($2,430, $4,860) (37.2, 21.3) (86.6, 43.3) (123.8, 64.7)
Two SIFs $194,406 19 % 59 160 $1,215 $3,295 28.9 63.9 92.8
(26 %, 13 %) (79, 38) (207, 104) ($939, $1,869) ($2,460, $5,116) (37.4, 18.8) (85.6, 41.2) (122.9, 60.0)
Three SIFs $291,609 18 % 66 179 $1,629 $4,418 21.6 47.7 69.2
(24 %, 12 %) (88, 44) (237, 118) ($1,230, $2,471) ($3,314, $6,628) (28.6, 14.2) (63.5, 31.8) (92.1, 46.0)
Four SIFs $388,812 16 % 75 202 $1,925 $5,184 18.3 40.6 58.9
(22 %, 11 %) (99, 50) (266, 133) ($1,462, $2,923) ($3,927, $7,776) (24, 12) (53.6, 27.1) (77.7, 39.1)
Five SIFs $486,015 15 % 84 226 $2,151 $5,785 16.3 36.9 52.7
(19 %, 10 %) (113, 56) (311, 148) ($1,563, $3,284) ($4,301, $8,679) (22.5, 10.7) (49, 24.3) (71.4, 35.0)
Six SIFs $583,218 13 % 93 251 $2,323 $6,271 15.1 33.6 48.7
(18 %, 9 %) (123, 62) (325, 163) ($1,795, $3,578) ($4,741, $9,407) (19.6, 9.8) (44.4, 22.4) (63.9, 32.2)
Seven SIFs $680,421 12 % 102 274 $2,483 $6,671 14.2 31.6 45.7
(15 %, 8 %) (135, 68) (370, 177) ($1,839, $3,844) ($5,040, $1,006) (19.1, 3.51) (41.8, 21) (61.0, 30.2)
Note: The numbers in parentheses represent the results of the sensitivity analysis: (40 per cent sharing rate, 20 percent sharing rate)
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(see Tables 2, 3 and 4). As with Andresen and Boyd [3],
Andresen and Jozaghi [4], Jozaghi [27, 28], Jozaghi and
Jackson [30], Jozaghi et al. [32], Jozaghi et al. [31], and
Jozaghi et al. [33], the current analysis used sharing
rate deviations for the sensitivity analysis; 40 and 20
per cent initial needle-sharing rates were used to
account for uncertainties in the models. The results
from both the baseline and sensitivity analyses demon-
strate that the unsanctioned SIF by VANDU has saved
taxpayers’ money, and should be expanded to prevent
further HCV and HIV cases.
Discussion
This analysis reviewed and utilized a cost-benefit/cost-
effectiveness analysis in order to determine whether
operating an unsanctioned SIF, where peers were actively
engaged in operating the facility and were able to offer
assisted injection, was an efficient use of public health
resources. The value of averted HIV and HCV cases far
outweighs the cost of SIFs and the equipment employed.
Moreover, additional unsanctioned SIFs operated by
peer-drug users would be a good value for the resources
they consume. In fact, the results here suggest that add-
itional peer-run SIFs that can offer assisted injection will
benefit the publically funded health care system, even
more than other potential cost-savings such as the pre-
vention of endocarditis, overdose deaths, subcutaneous
abscesses, cellulitis, and soft-tissue infections.Nevertheless, it should be noted that this study did
not rely on a more complex method that considers
quality-adjusted life years (QALYs). In effect, the
methods and models employed in this study may be
considered rudimentary in comparison to more com-
plex models used previously by Bayoumi and Zaric [5]
or Bayoumi et al. [6] in the area of costing studies of
SIF. This model did not formally take into account the
dynamics of the social system and a score of parame-
ters such as increase in detoxifications, methadone
treatments, or secondary HIV transmission through
sexual contact. Rather, it employed static mathematical
models that only consider the reduction in HIV and
HCV cases linearly. Such models are typically used to
evaluate needle exchange programs [24, 34].
Moreover, in this study, the medical cost of incident
HIV has significantly underestimated the cost of treat-
ment, diagnosis, clinical care, and lifelong provisions
of medication such as ART. Furthermore, the cost of
hospitalizations for HIV-related complications have
also been significantly underestimated in the current
study since PWID are commonly known to end up
using hospital services because of the complications
related to HIV [53, 64]. Consequently, the estimated
lifetime healthcare costs of an HIV diagnosis is nearly
double the estimate presented in this research (e.g.,
US$326,500 or CAN$409,725) [53, 64].
These models have been previously adapted to the
context of SIFs by a number of peer-reviewed studies
Table 3 The marginal annual cost - effectiveness and cost – benefit of unsanctioned SIF in Vancouver using Jacobs et al.’s [24] model
Variables Annual cost of
operation














One SIF $97,203 25 % 30 81 $1,200 $3,240 29.3 64.9 94.3
(33 %, 16 %) (40, 20) (103, 59) ($944, $1,648) ($2,430, $4,860) (37.2, 21.3) (86.6, 43.3) (102.2, 64.7)
Two SIFs $97,203 19 % 29 79 $1,230 $3,352 28.6 62.8 91..4
(26 %, 13 %) (39, 38) (103, 104) ($944, $1,869) ($2,492, $5,116) (37.2, 18.8) (84.5, 41.2) (121.7, 60.0)
Three SIFs $97,203 18 % 7 19 $5,115 $13,886 6.9 15.2 22.0
(24 %, 12 %) (9, 44) (29, 118) ($3,352, $2,471) ($10,800, $6,628) (10.5, 14.2) (19.5, 31.8) (25.7, 46.0)
Four SIFs $97,203 16 % 8 23 $4,226 $12,150 8.3 17.3 25.6
(22 %, 11 %) (12, 50) (29, 133) ($3,352, $2,923) ($8,100, $7,776) (10.5, 12) (26, 27.1) (25.6, 39.1)
Five SIFs $97,203 15 % 9 24 $4,050 $10,800 8.7 19.5 28.2
(19 %, 10 %) (14, 56) (44, 148) ($2,209, $3,284) ($6,943, $8,679) (15.9, 10.7) (30.3, 24.3) (28.2, 35.0)
Six SIFs $97,203 13 % 9 25 $3,888 $10,800 9 19.5 28.5
(18 %, 9 %) (10, 62) (14, 163) ($6,943, $3,578) ($9,720, $9,407) (5.1, 9.8) (21.6, 22.4) (26.7, 32.2)
Seven SIFs $97,203 12 % 8 22 $4,418 $12,150 7.9 17.3 25.3
(15 %, 8 %) (12, 68) (44, 177) ($2,209, $3,844) ($8,100, $1,006) (15.9, 3.51) (26, 21) (33.2, 30.2)
Note: The numbers in parentheses represent the results of the sensitivity analysis: (40 per cent sharing rate, 20 percent sharing rate)
Jozaghi Health and Justice  (2015) 3:16 Page 7 of 10[3, 4, 27, 28, 30, 31, 33, 60, 61]. They have proven to be
instructive and realistic, generating results that have
been verified with known occurrences of HIV and
HCV. For example, Jozaghi et al’s [33] analysis of estab-
lishing SIFs in Ottawa estimated approximately the
same amount of HIV and HCV infections, in addition
to relying on calculations made by other authors, suchTable 4 The cumulative and marginal cost - effectiveness and cost
O’Keefe’s [34] model
Variables Annual cost of operation Sharing rate # of H
One SIF $97,203 25 % 10
($97,203) (10)
Two SIFs $194,406 19 % 19
($97,203) (9)
Three SIFs $291,609 18 % 21
($97,203) (2)
Four SIFs $388,812 16 % 23
($97,203) (3)
Five SIFs $486,015 15 % 27
($97,203) (3)
Six SIFs $583,218 13 % 30
($97,203) (3)
Seven SIFs $680,421 12 % 32
($97,203) (3)
Note: The numbers in parentheses represent the marginal resultsas Bayoumi et al. [6], that have used more complex
models that consider QALYs. In effect, in some in-
stances, the complex models based on QALYs have
been criticized for over estimating the number of pre-
vented cases of HIV and HCV [10].
The success rates of such programs, according to
Jozaghi [29] and Des Jarlais et al. [10]), is based on– benefit of unsanctioned SIF in Vancouver using Kaplan and















Jozaghi Health and Justice  (2015) 3:16 Page 8 of 10locating SIFs where drug users live and in settings with
high rates of public drug use. The current SIF, known
to many Canadians as Insite, despite various restric-
tions, has proven effective in reducing injections in
public, while lowering the rate of fatalities caused by
overdose and infectious diseases [35, 36, 48, 74]. More-
over, Insite has not resulted in increased rates of crime,
drug dealing, public injection, public syringe disposal,
or public disorder around its vicinity [11, 16, 66].
Therefore, such benefits as the one noted above, could
potentially be expanded with additional SIFs that could
accommodate various PWID.
In summary, this study, through the use of two
mathematical models, has shown that the former un-
sanctioned SIF in Vancouver was extremely cost-
effective. The models in this paper are similar to those
used by Andresen and Boyd [3], Andresen and Boyd
[3]) and Jozaghi et al. [32]), Jozaghi et al. [33] and
Jozaghi [27, 28]), which have demonstrated the cost-
effectiveness of SIFs and supervised smoking facilities
in various Canadian settings. This paper shows that
the number of new HIV and HCV infections averted,
and the associated benefits and cost-effectiveness, are
more than enough to cover the cost of operating more
than one SIF in Vancouver that could potentially be
operated by peers who can offer assisted injection. As
result, the findings of this costing study and the Quali-
tative study by McNeil et al. [51] have shown the
critical role that unsanctioned SIFs, despite not having
a license to operate legally, could play in reducing
blood-borne infections and saving health care costs
Ultimately, the closure of the small facility by VANDU,
a consequence of a threat by their funding agency, Van-
couver Coastal Health, has been problematic, potentially
placing many PWID at increased risk of contracting
HIV and HCV infections. The concept of a peer-driven
unsanctioned SIF, where drug users can assist their peers
inject, could be relevant to many U.S. cities such as
San Francisco, Baltimore and New York that are facing
health concerns attributed to injection drug use. An un-
sanctioned SIF in the noted US cities would increase
access to lifesaving services and would serve to restore
some dignity and respect to the lives of many drug users
who are placed at increased risk because of their relaps-
ing medical condition.
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